Phase 3 randomized, placebo-controlled, double-blind trial of risedronate for the prevention of bone loss in premenopausal women undergoing chemotherapy for primary breast cancer

Abstract

Risedronate did not prevent bone loss in premenopausal women undergoinng adjuvant chemotherapy for breast cancer.

Keywords

• Risedronate
• treatment for breast cancer
• premenopausal women